Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US company Adventrx Pharmaceuticals has presented clinical trial data related to its phase II CoFactor product at the Gastrointestinal Cancers Symposium in San Francisco.
Subscribe to our email newsletter
The company has said that objective results from an independent radiology organization concluded the treatment resulted in an overall clinical benefit of 85%. Adventrx also reported longer than expected time to tumor progression (TTP), with no drug-related grade 3 or grade 4 gastrointestinal or hematological toxicities.
“The high level of activity and low toxicity of CoFactor suggests that this combination may prove useful as an initial treatment for metastatic colorectal cancer, especially among patients who would benefit from minimizing toxicity. These results give us added confidence as we proceed to our phase III pivotal study,” said Evan Levine, president of Adventrx.